News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ICON-PLC (ICLR) Central Laboratories Launches iSite Portal for Investigator Sites


11/27/2012 11:37:05 AM

Dublin, Ireland, 27 November 2012 - ICON plc (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the launch of iSite, a secure web-based portal that drives efficiency by providing investigators 24-hour access to study-specific laboratory information from ICON Central Laboratories.

iSite is an easy-to-use portal that allows investigators and other site personnel to access electronic laboratory reports for their active studies at any time. It includes user-friendly navigation, filtering and report management and provides investigators customised views of reports by study, site, subject or visit date. iSite also includes email alert functionality which notifies investigators when new reports become available.

“We are continuously looking to introduce innovative technology solutions that drive efficiency and improve performance,” commented Tom O’Leary, President, ICON Central Laboratories. “iSite provides investigators a much needed solution for accessing important study-specific information in the most rapid, secure and convenient way possible.”

A future release of iSite is in development and will provide sites with study-specific performance metrics and additional tools such as customised electronic laboratory manuals which will be created by ICON’s Firecrest™ technology. ICON’s Firecrest delivers an innovative suite of training and study management tools which can significantly improve the compliance, consistency and execution of study-related activities at investigator sites.

About ICON plc

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has approximately 9,300 employees, operating from 82 locations in 40 countries.

Further information is available at www.iconplc.com

DISCLOSURE NOTICE: The information contained in this release is as of 27 November 2012. The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. A description of risks and uncertainties relating to ICON and its business can be found in ICON’s Annual Report for the fiscal year ended December 31, 2011 and in the forms filed with the US Securities and Exchange Commission, including the Forms 20-F, F-1, S-8 and F-3. ICON disclaims any intent or obligation to update these forward-looking statements.


Read at BioSpace.com


comments powered by Disqus
ICON-PLC
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES